Cargando…
Therapeutic Potential of Intracerebroventricular Replacement of Modified Human β-Hexosaminidase B for GM2 Gangliosidosis
To develop a novel enzyme replacement therapy for neurodegenerative Tay-Sachs disease (TSD) and Sandhoff disease (SD), which are caused by deficiency of β-hexosaminidase (Hex) A, we designed a genetically engineered HEXB encoding the chimeric human β-subunit containing partial amino acid sequence of...
Autores principales: | Matsuoka, Kazuhiko, Tamura, Tomomi, Tsuji, Daisuke, Dohzono, Yukie, Kitakaze, Keisuke, Ohno, Kazuki, Saito, Seiji, Sakuraba, Hitoshi, Itoh, Kohji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3129794/ https://www.ncbi.nlm.nih.gov/pubmed/21487393 http://dx.doi.org/10.1038/mt.2011.27 |
Ejemplares similares
-
Combined replacement effects of human modified β-hexosaminidase B and GM2 activator protein on GM2 gangliosidoses fibroblasts
por: Kitakaze, Keisuke, et al.
Publicado: (2016) -
Lyso-GM2 Ganglioside: A Possible Biomarker of Tay-Sachs Disease and Sandhoff Disease
por: Kodama, Takashi, et al.
Publicado: (2011) -
Intracerebroventricular enzyme replacement therapy with β-galactosidase reverses brain pathologies due to GM1 gangliosidosis in mice
por: Chen, Joseph C., et al.
Publicado: (2020) -
Genetics and Therapies for GM2 Gangliosidosis
por: Cachón-González, María Begoña, et al.
Publicado: (2018) -
GM1 Gangliosidosis: Mechanisms and Management
por: Rha, Allisandra K, et al.
Publicado: (2021)